UBS WARBURG
March 1st, 2002
BY PHILIP FINE
SEVERAL drugs companies have been temporarily inflating revenue through frequent price increases, according to an analysis by American investment firm UBS Warburg.
The study tracked price increases and inventory levels from this past autumn and found that drugs firms have been informing wholesalers of upcoming price changes, leading distributors to buy larger amounts of medicines ahead of the increases.
Schering-Plough's earnings could have been as much as 14 percent lower last year if wholesalers had reduced their inventories to a normal ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.